We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+33.14%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$7.1B
AUM Growth
+$1.15B
Cap. Flow
-$108M
Cap. Flow %
-1.52%
Top 10 Hldgs %
31.14%
Holding
166
New
24
Increased
29
Reduced
28
Closed
31

Top Buys

Rank Stock Value
1
BNR
Burning Rock Biotech
BNR
+$130M
2
RPTX
Repare Therapeutics
RPTX
+$110M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$93.3M
4
BIIB icon
Biogen
BIIB
+$70.8M
5
TBPH icon
Theravance Biopharma
TBPH
+$60.2M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$237M
2
PFE icon
Pfizer
PFE
+$98.3M
3
GILD icon
Gilead Sciences
GILD
+$98M
4
ALEC icon
Alector
ALEC
+$64.9M
5
HCA icon
HCA Healthcare
HCA
+$63.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.96%
2 Financials 1.61%
3 Miscellaneous 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALC icon
76
Alcon
ALC
$32.8B
$20.2M 0.28%
351,380
– –
BFYT
77
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
$19.7M 0.28%
962,900
– –
AUPH icon
78
Aurinia Pharmaceuticals
AUPH
$2.15B
$19.4M 0.27%
1,196,347
-140,200
-10% -$2.24M
REGN icon
79
Regeneron Pharmaceuticals
REGN
$79.7B
$19.3M 0.27%
30,900
+13,700
+80% +$7.78M
CRVS icon
80
Corvus Pharmaceuticals
CRVS
$1.09B
$18.4M 0.26%
6,767,584
– –
SRRA
81
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$17.9M 0.25%
1,477,320
– –
ISEE
82
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$16.6M 0.23%
3,250,000
+2,500,000
+333% +$10.4M
VRCA icon
83
Verrica Pharmaceuticals
VRCA
$78.7M
$16.3M 0.23%
147,973
– –
SNDX icon
84
Syndax Pharmaceuticals
SNDX
$1.62B
$16.2M 0.23%
1,094,100
+804,100
+277% +$12.2M
OBSV
85
DELISTED
ObsEva SA Ordinary Shares
OBSV
$15.3M 0.22%
2,605,531
– –
GILD icon
86
Gilead Sciences
GILD
$181B
$14.8M 0.21%
192,200
-1,278,900
-87% -$98M
NMTR
87
DELISTED
9 Meters Biopharma
NMTR
$14.6M 0.21%
+1,285,838
New +$14.5M
FBRX
88
DELISTED
Forte Biosciences
FBRX
$13.9M 0.2%
+38,013
New +$17M
TECX
89
Tectonic Therapeutic
TECX
$557M
$13.8M 0.2%
66,143
+10,878
+20% +$2.24M
HLSQ
90
Tessera Defense and Homeland Security Inc.
HLSQ
$2.61M
$12.8M 0.18%
1,218
– –
XLRN
91
DELISTED
Acceleron Pharma
XLRN
$12.1M 0.17%
127,500
-130,049
-50% -$12.5M
LRMR icon
92
Larimar Therapeutics
LRMR
$406M
$12M 0.17%
933,960
+841,749
+913% +$9.8M
LAB icon
93
Standard BioTools
LAB
$271M
$11.7M 0.16%
+2,907,100
New +$10.1M
ALXN
94
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$11.2M 0.16%
+100,000
New +$10.6M
ARCT icon
95
Arcturus Therapeutics
ARCT
$450M
$11.2M 0.16%
+239,186
New +$8.24M
CTIC
96
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$11M 0.16%
9,520,600
– –
GNMK
97
DELISTED
GenMark Diagnostics, Inc
GNMK
$10.8M 0.15%
+732,000
New +$7.44M
ACET icon
98
Adicet Bio
ACET
$79.7M
$10.4M 0.15%
43,128
– –
XFOR icon
99
X4 Pharmaceuticals
XFOR
$359M
$10.1M 0.14%
36,216
– –
ABBV icon
100
CALL
AbbVie
ABBV
$465B
$9.82M 0.14%
+100,000
New +$8.8M
2 3
4
5 6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2020 Portfolio in Review

As of Q2 2020, OrbiMed held 166 positions worth $7.1B, up 19% from $5.95B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

OrbiMed's Q2 2020 filing shows 24 new, 29 increased, 28 reduced and 31 closed positions. Its largest new stake was Burning Rock Biotech: 474,607 shares worth $128M. The largest sale was Ascendis Pharma A/S, an estimated $237M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials and Miscellaneous.

  • OrbiMed's largest Q2 2020 buy was Burning Rock Biotech: 474,607 shares worth $128M.
  • OrbiMed added most to Biogen in Q2 2020, an estimated $70.8M increase.
  • OrbiMed's biggest Q2 2020 reduction was Ascendis Pharma A/S, cutting an estimated $237M.
  • OrbiMed fully exited Pfizer in Q2 2020, selling an estimated $98.3M.
  • OrbiMed's ten largest holdings make up 31% of its $7.1B portfolio in Q2 2020.
  • OrbiMed opened 24 new positions and closed 31 in Q2 2020.
  • OrbiMed's portfolio value rose 19% quarter-over-quarter to $7.1B.

Based on OrbiMed's 13F filing for Q2 2020, filed 14 Aug 2020.